Two – Drug Combination Produces Strong results in late-stage ovarian cancer Phase II studyresearchers were surprised that late ovarian cancer patients responded well to the experimental carboplatin – decitabine combination therapy given that they resistant to carboplatin. Indiana University researchers are committed to conduct a larger study in humans in order to test the two-drug combination with existing treatment of ovarian cancer.
This research was funded by the NIH , National Cancer Institute, Walther Cancer Foundation, and the Ovarian Cancer Research Foundation.
Statins a well-tolerated and extensively studied group of drugs, their proven impact on cardiovascular disease risk has been driving their widespread use are. ‘With a few caveats, and in anticipation of good quality randomized data for the newer drugs statins seem to be a remarkably safe group of drugs when used at their usual doses.Given the positive outcomes of this meeting Innocoll planning file an IND at second quarter of 2007 submit it for the target indication prevention postoperative intra-abdominal infections to patients with an open breast and Visceral Surgery in addition to standard infection prophylaxis.. Innocoll a privately held pharmaceutical company which, announcing that after an pre – Investigational New Drug application sessions has the U.S. Food and Drug Administration Innocoll proposal, developing his CollaRx GENTAMICIN accepts begin surgical graft in USA in the phase 3.
Orjan Friberg, cardiac surgeon at Orebro University Hospital conducted. To patients the treated group were two gentamycin Implants placed between sternal halves before closure. The primary endpoint was 9.0 percent in control group and 4.. Is Innocoll Duke University in Duke Clinical Research Institute as the Study Coordinating Centre for the two planned appointment U.S. Multicentre phase 3 clinical studies open heart and colorectal surgery. The design the first of these two studies in patients after cardiac surgery will be shown with to a recently published clinical trials in 2000 patients, 4 to to gentamicin implants incidence of sternal wound infected reduced by 53 percent if used as an addition about there based default infection control.